Compare FSM & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSM | INDV |
|---|---|---|
| Founded | 1990 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2005 | 2014 |
| Metric | FSM | INDV |
|---|---|---|
| Price | $9.58 | $34.13 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 1.4M |
| Earning Date | 05-06-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 1.64 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $38.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $14.10 | $20.92 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $5.33 | $10.91 |
| 52 Week High | $13.85 | $38.00 |
| Indicator | FSM | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 61.79 |
| Support Level | $9.33 | $33.15 |
| Resistance Level | $9.95 | $35.75 |
| Average True Range (ATR) | 0.35 | 1.26 |
| MACD | -0.05 | 0.30 |
| Stochastic Oscillator | 5.93 | 77.51 |
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).